Nurix Therapeutics (NRIX) Expected to Release Quarterly Earnings on Thursday

Nurix Therapeutics (NASDAQ:NRIX) will likely be issuing its Q3 2026 results after the market closes on Thursday, October 8th. Analysts expect the company to post earnings of ($0.6009) per share and revenue of $24.3480 million for the quarter. Parties are encouraged to explore the company’s upcoming Q3 2026 earning summary page for the latest details on the call scheduled for Thursday, October 15, 2026 at 4:00 PM ET.

Nurix Therapeutics (NASDAQ:NRIX) last announced its quarterly earnings data on Thursday, July 9th. The company reported ($0.81) EPS for the quarter, missing analysts’ consensus estimates of ($0.73) by ($0.08). Nurix Therapeutics had a negative return on equity of 76.09% and a negative net margin of 928.44%.The business had revenue of $9.04 million during the quarter, compared to the consensus estimate of $15.29 million. On average, analysts expect Nurix Therapeutics to post $-3 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Nurix Therapeutics Price Performance

Shares of NASDAQ:NRIX opened at $22.88 on Tuesday. The stock has a market capitalization of $2.37 billion, a PE ratio of -6.63 and a beta of 1.82. The company’s 50-day moving average price is $25.33 and its two-hundred day moving average price is $20.69. Nurix Therapeutics has a one year low of $9.00 and a one year high of $28.23.

Wall Street Analyst Weigh In

Several research analysts have weighed in on the company. BTIG Research reaffirmed a “buy” rating and set a $32.00 price target on shares of Nurix Therapeutics in a research report on Friday, July 10th. HC Wainwright upped their target price on shares of Nurix Therapeutics from $32.00 to $34.00 and gave the company a “buy” rating in a report on Friday, July 10th. Mizuho raised their target price on shares of Nurix Therapeutics from $30.00 to $34.00 and gave the company an “outperform” rating in a research note on Monday, July 13th. Robert W. Baird lifted their price target on Nurix Therapeutics from $26.00 to $33.00 and gave the stock an “outperform” rating in a report on Thursday, June 18th. Finally, Oppenheimer initiated coverage on Nurix Therapeutics in a research report on Monday, June 29th. They set an “outperform” rating and a $28.00 price target on the stock. Thirteen investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Nurix Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus target price of $34.21.

Insider Activity at Nurix Therapeutics

In related news, CFO Hans van Houte sold 4,761 shares of the stock in a transaction that occurred on Tuesday, August 4th. The stock was sold at an average price of $24.36, for a total transaction of $115,977.96. Following the sale, the chief financial officer owned 40,166 shares of the company’s stock, valued at $978,443.76. This represents a 10.60% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Gwenn Hansen sold 1,452 shares of the stock in a transaction on Tuesday, September 1st. The stock was sold at an average price of $25.47, for a total value of $36,982.44. Following the sale, the insider directly owned 117,227 shares in the company, valued at approximately $2,985,771.69. This trade represents a 1.22% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders sold 21,372 shares of company stock valued at $518,463. 6.70% of the stock is currently owned by corporate insiders.

About Nurix Therapeutics

Nurix Therapeutics, Inc is a biopharmaceutical company focused on developing medicines that regulate the levels and activity of disease-causing proteins. Headquartered in San Francisco, California, the company uses its DELigase platform to discover therapies based on targeted protein degradation and immune-system modulation.

Nurix’s pipeline includes oral targeted protein degraders designed to eliminate specific proteins involved in cancer and immune-cell function. Its lead programs have included NX-5948, a Bruton’s tyrosine kinase degrader being evaluated for certain B-cell malignancies, and NX-2127, an investigational degrader designed to target BTK and other proteins relevant to cancer biology.